REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program TrendingStockAlerts · Jan 13, 2026
Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 TrendingStockAlerts · Jan 12, 2026
Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA) TrendingStockAlerts · Jan 11, 2026
Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology TrendingStockAlerts · Jan 10, 2026
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD TrendingStockAlerts · Jan 9, 2026
AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board TrendingStockAlerts · Jan 8, 2026
CIMG Inc. Announces Entry into Computing Power Industry; Initial Contracts with Aggregate Value of Approximately $124 Million TrendingStockAlerts · Jan 7, 2026
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy TrendingStockAlerts · Jan 6, 2026
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference TrendingStockAlerts · Jan 5, 2026
MarathonLS and Pacer Announce Strategic Separation into Two Independent Organizations TrendingStockAlerts · Jan 4, 2026
Last day of trading in shares with pre-emptive rights in connection with rights issue TrendingStockAlerts · Jan 3, 2026
